GE HealthCare Technologies Inc.

GE HealthCare Technologies Inc.

GEHC
GE HealthCare Technologies Inc.US flagNASDAQ Global Select
62.03
USD
+0.04
- -
28.22BMarket Cap
GE HealthCare Technologies Inc.
GEHC
(NASDAQ Global Select)

Recent

price

62.03

P/E

ratio

- -

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
TTM
FRC
36.58
37.75
38.67
44.32
42.97
43.14
45.23
45.98
Revenue per Share
3.35
30.45
4.94
4.63
3.04
4.37
4.57
4.19
Basic EPS, GAAP
3.65
3.14
2.98
4.36
3.77
3.4
3.3
3.33
Free Cash Flow per Basic Share
- -
- -
- -
- -
0.09
0.12
0.14
0.14
Dividend per Share
- -
34.23
38.91
27.15
2.93
7.16
11.59
12.4
Book Value per Share
- -
2.81
4.74
-11.46
-15.12
-12.2
-8.82
-13.3
Tangible Book Value per Share
455
455
455
414
455
456
456
456
Basic Weighted Avg Shares
16,633
17,164
17,585
18,341
19,552
19,672
20,625
20,979
Sales/Revenue/Turnover
12.77
15.85
15.89
13.75
12.45
13.34
13.39
12.63
Operating Margin (%)
659
630
625
633
610
580
578
595
Depreciation Expense
1,524
13,846
2,247
1,916
1,568
1,993
2,084
1,910
Net Income, GAAP
19.61
24.06
20.87
22.41
31.47
20.57
22.18
23.43
Effective Tax Rate (%)
9.16
80.67
12.78
10.45
8.02
10.13
10.1
9.1
Profit Margin (%)
- -
-628
239
1,127
429
348
3,396
1,897
Working Capital
- -
336
327
8,516
8,747
7,759
9,821
10,438
LT Debt
- -
14,751
16,896
9,592
7,310
8,652
10,599
10,898
Total Equity
- -
26.64
13.37
10.86
9.3
11.67
10.83
9.99
Return on Invested Capital (%)
- -
172.44
12.97
10.04
12.03
19.3
16.35
14.61
Return on Capital (%)
- -
177.9
13.51
13.25
22.04
86.69
48.73
40.32
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
2,139
642
139
LT Borrowings
8,277
9,495
10,127
LT Finance Leases
328
326
311
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
456
456
455
Market Capitalization
34,302
37,442
32,476

Working Capital

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
11,893
12,501
10,426
Cash, Cash Equivalents & STI
4,005
4,492
2,261
Accounts Receivable, Net
3,474
3,719
3,465
Inventories
2,304
2,234
2,353
Total Current Liabilities
10,073
9,105
8,529
Payables & Accruals
3,568
3,871
3,990
ST Debt
2,139
642
139
Deferred Revenue
2,002
2,095
2,153

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-2.32%
22.5%
Free Cash Flow
- -
2.12%
-2.9%
Net Income, GAAP
- -
-17%
4.57%
Sales/Revenue/Turnover
- -
3.76%
4.84%
Total Cash Common Dividend
- -
- -
16.36%

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
4,650
4,839
4,863
5,319
19,672
2025
4,777
5,006
5,144
5,698
20,625
2026
5,131
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.82
0.94
1.03
1.58
4.37
2025
1.23
1.06
0.98
1.29
4.57
2026
0.85
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.03
0.03
0.03
0.03
0.12
2025
0.04
0.04
0.04
0.04
0.14
2026
0.04
- -
- -
- -
- -
Business
GE HealthCare Technologies Inc. specializes in the design, production, and global distribution of advanced products, extensive services, and integrated digital platforms aimed at patient diagnostics, therapeutic interventions, and ongoing monitoring across numerous international regions. The organization structures its operations into four distinct divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division delivers sophisticated molecular imaging, computed tomography (CT), magnetic resonance (MR), image-guided therapy, and X-ray systems, alongside specialized offerings for women's health screening. The Ultrasound division offers solutions for the detection, assessment, treatment, and continuous oversight of various conditions through applications in radiology, primary care, cardiovascular health, women’s health, and handheld point-of-care devices, also incorporating surgical visualization and guidance products with AI-enabled productivity tools. The Patient Care Solutions division is dedicated to furnishing medical devices, essential consumables, supportive services, and intelligent digital tools for patient monitoring, anesthesia delivery and respiratory management, diagnostic cardiology, and maternal and infant care. The Pharmaceutical Diagnostics division supplies a range of diagnostic agents, including contrast media for CT, angiography, X-ray, and MR scans, as well as single-photon emission computed tomography and positron emission tomography, to the radiology and nuclear medicine sectors. This segment also provides pharmaceuticals administered prior to imaging to enhance tissue visibility and molecular imaging agents, which are radiopharmaceuticals with radioisotopes used for diagnostic scans. The company was established as a corporate entity in 2022 and maintains its primary corporate offices in Chicago, Illinois. In a significant recent development, the company has agreed to acquire Intelerad, a medical imaging software provider, for $2.3 billion, a move set to substantially enhance its cloud-based and AI-enabled imaging solutions, particularly expanding its reach into outpatient and teleradiology markets. This acquisition is expected to accelerate GE HealthCare's transition to a software-as-a-service (SaaS) business model and significantly boost its recurring revenue.

Company News

APIChat
  • GE HealthCare Technologies Inc. (GEHC) Presents at Jefferies Global Healthcare Conference 2026 Transcript

  • GE HealthCare Focuses on Expanding Access to Nuclear Medicine Through AI, Radiopharmaceutical and Imaging Innovations

  • GE HealthCare Technologies: Doing Some Bottom Fishing

  • GE HealthCare (GEHC) Up 3.3% Since Last Earnings Report: Can It Continue?

  • GE HealthCare and UW Medicine Radiology Expand CT, MI Research Tie

  • GE HealthCare Technologies Inc. (GEHC) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

  • Securities Fraud Investigation Into GE HealthCare Technologies Inc. (GEHC) Continues -- Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

  • Securities Fraud Investigation Into GE HealthCare Technologies Inc. (GEHC) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

  • Securities Fraud Investigation Into GE HealthCare Technologies Inc. (GEHC) Continues -- Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Fi

  • Securities Fraud Investigation Into GE HealthCare Technologies Inc. (GEHC) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

  • GEHC INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving GE HealthCare Technologies Inc.

  • GEHC INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving GE HealthCare Technologies Inc.

  • GEHC INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving GE HealthCare Technologies Inc.

  • GEHC INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving GE HealthCare Technologies Inc.

  • Bragar Eagel & Squire, P.C. Continues Investigating GE HealthCare Technologies Inc. on Behalf of GE HealthCare Stockholders and Encourages Investors to Contact the Firm

  • Securities Fraud Investigation Into GE HealthCare Technologies Inc. (GEHC) Announced -- Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Fi

  • Securities Fraud Investigation Into GE HealthCare Technologies Inc. (GEHC) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

  • GE HealthCare Technologies Inc. (GEHC) Shareholders Who Lost Money -- Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

  • GE HealthCare Technologies Inc. (GEHC) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

  • GE HealthCare Technologies Sticks to Growth Story After Inflation-Driven Guidance Cut